Squarepoint
JSPR icon

Squarepoint’s Jasper Therapeutics JSPR Stock Holding History

Squarepoint’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,915
Closed -$56.9K – 4704
2026
Q1 		$56.9K Sell
64,915
-217,011
-77% -$301K ﹤0.01% 4129
2025
Q4 		$516K Buy
281,926
+267,966
+1,920% +$538K ﹤0.01% 3196
2025
Q3 		$33.2K Sell
13,960
-11,419
-45% -$34.6K ﹤0.01% 4260
2025
Q2 		$141K Buy
+25,379
New +$125K ﹤0.01% 4079
2023
Q2 		– Sell
-13,989
Closed -$253K – 3791
2023
Q1 		$253K Buy
+13,989
New +$259K ﹤0.01% 2666

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's JSPR Position: Q2 2026 in Review

Squarepoint sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 64,915 shares — an estimated $56.9K sold.

Squarepoint first reported a position in JSPR in Q1 2023 and held it in 5 quarters. The position peaked at $516K in Q4 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Squarepoint reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 64,915 Jasper Therapeutics shares in Q2 2026, an estimated $56.9K.
  • Squarepoint first reported a position in Jasper Therapeutics in Q1 2023 and held it in 5 quarters.
  • Squarepoint's Jasper Therapeutics position peaked at $516K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.